-
Doing the right thing doesn't guarantee that everyone is going to be pleased, says Frederick S. Southwick, MD, professor of medicine in the Division of Infectious Diseases and quality projects manager for the senior vice president for health affairs at the University of Florida Shands Health in Gainesville.
-
The needle is beginning to move. Four key healthcare associated infections (HAIs) are declining nationally as the result of unprecedented interest and action that includes everything from sweeping state and federal collaboratives to the outrage of individual patients.
-
The Joint Commission targets central lineassociated bloodstream infections in its 2011 national patient safety goals, with NPSG.07.04.01 calling for hospitals to "implement evidence-based practices to prevent (CLABSIs)."
-
[Editor's note: In this issue we continue with the second part of Patti Grant's IP Newbie column that was featured in our September issue. As you may recall, she described an all too common situation: How various professionals in healthcare are expected to participate in activities beyond their original area of expertise. This expectation does not seem so much a direct consequence of the struggling economy as a reflection of the attempt by various specialties to move from "silos" to a team approach to problem solving, Grant noted, observing that "Patient safety will most likely be less precarious in this multi-disciplinary improvement environment, but it can come with hefty growing pains." Of course, as an IP Newbie, you're often the one growing.]
-
The Joint Commission's new National Patient Safety Goal (NPSG) on preventing indwelling catheter-associated urinary tract infections which emphasizes prompt removal of unnecessary devices and surveillance for CAUTIs is effective January 1, 2012 for hospitals.
-
With the increasing reliance on computer tools and electronic records, infection preventionists may reasonably assume patients flagged for isolation on admission end up under the appropriate precautions.
-
The elements of performance for the CAUTI prevention safety goal are as follows:
-
Updates to the darunavir (Prezista®) package insert, specifically sections: 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on Oct. 19, 2011, to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, "A randomized, controlled, open-label Phase 3 trial comparing darunavir/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects."
-
Thirty years after the world first became aware of a strange syndrome that caused young men to acquire rare diseases like Pneumocystis carinii pneumonia (PCP) and Kaposi's Sarcoma, nations across the globe continue to battle against the HIV/AIDS epidemic.
-
One obstacle to the success of the U.S. national HIV/AIDS strategy involves the accuracy of metrics used for monitoring HIV care, including late diagnoses and linkage to sustained care, a new study notes.
